

What is claimed is:

1. A system for creating and using data associated with a product or device, comprising:
 - at least one adverse event database for storing adverse event data associated with a commercially available product or device;
 - processor for accessing and analyzing data from the at least one adverse event database to assist in identifying new essential adverse events associated with the product or device and to assist in identifying at least one new useful characteristic of, or use for, the product or device responsive to identification of at least one new essential adverse event associated with the product or device;
 - adverse event information storage device for storing the new essential adverse event data identified by the processor;
 - user computer for making requests for essential adverse event information to, and for receiving adverse event information from, the processor; and
 - user interface for interfacing the processor and the user computer.
2. The system of claim 1, wherein at least one adverse event database comprises raw data from a plurality of different adverse events.
3. The system of claim 1, wherein data from at least one database comprises previously known or reported adverse event information regarding exposure to or use of the product or device.
4. The system of claim 3, wherein data from at least one database further comprises information regarding adverse events selected from the group consisting of death, illness, hospitalization, missed work, medical costs, abnormal laboratory results and surgeries.
5. The system of claim 3, wherein at least one database comprises raw adverse event data linked with exposure to or use of the product or device.
6. The system of claim 5, wherein at least one database comprises information relating to patents and patent applications.

7. The system of claim 1, wherein the at least one database comprises commercial or sales data.

8. The system of claim 1, wherein the at least one adverse event database comprises adverse event data gathered from at least 5000 subjects.

9. The system of claim 8, wherein the at least one adverse event database further comprises information regarding amount of use of the product or device or duration of exposure to the product or device by each subject.

10. The system of claim 8, wherein the at least one adverse event database further comprises information regarding product post-exposure adverse event data, which is recorded in selected time increments, ranging from less than one hour to more than ten years.

11. The system of claim 1, wherein the processor further comprises means for commercializing at least one new useful characteristic of, or use for the product or device after determining at least one new essential adverse event associated with exposure to or use of the product.

12. The system of claim 11, wherein commercialization comprises facilitating selling, leasing or licensing the newly identified product information.

13. The system of claim 11, wherein commercialization comprises facilitating protecting intellectual property interests in the newly identified product information.

14. The system of claim 11, wherein commercialization comprises formatting the data relating to at least one new essential adverse event associated with exposure to or use of the product or device, or documenting same, such that a manufacturer or distributor of the product or device must inform consumers, users or individuals responsible for the user, physicians or

prescribers about the at least one new essential adverse event associated with exposure to or use of the product or device.

15. The system of claim 1, further comprising means for determining the value of commercializing the at least one new characteristic or use determined from the at least one identified essential adverse event.

16. The system of claim 1, wherein the at least one new use of the product or device comprises a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

17. The system of claim 16, wherein the product or device is commercially available, and wherein the new use comprises restricting exposure to the product or device to one of the high risk associated groups selected from the groups consisting of high or low temperatures, chemicals, surfaces, pressures, electricity and sparks; or contact of the product or device with one of the group selected from the group consisting of skin, eyes, ears, respiratory surfaces, gastrointestinal surfaces and mucous membranes of the consumer; or exposure to a subpopulation group selected from the group consisting of children, pregnant women, consumers with specific allergies or medical conditions and animals; or exposure to a subpopulation defined by at least one consumer-identifying characteristic selected from the group consisting of sex, weight, age, race, genetic characteristics, medical condition, pregnancy status, presence of allergies, and use of medicines or medical devices; and wherein the system subsequently evaluates whether the product or device is commercially available.

18. A proprietary product or device created using the system of claim 1.

19. The product of claim 1, wherein the product is medical.

20. The product of claim 19, wherein the medical product is a generic drug.

21. The product of claim 1, wherein the product is non-medical.
22. The device of claim 1, wherein the device is medical.
23. The device of claim 1, wherein the device is non-medical.
24. A proprietary kit containing a product or device, and labeling notifying a user of at least one new essential adverse event for the product or device, wherein the kit being created in accordance with claim 1.
25. The method comprising using the proprietary kit of claim 24 in accordance with a proprietary new characteristic of, or use for, a product or device.
26. A proprietary new use for a commercially available product or device, wherein the new use is determined from the data provided by the system of claim 1.
27. The proprietary new use for a commercially available product or device according to claim 26, wherein the new use is protected as an intellectual property.
28. The proprietary new use for a commercially available product or device according to claim 26, wherein the use comprises a restricted use in one or more subgroups of consumers, wherein the use is based on demographic data, and for which use additional testing of the consumers is not needed.
29. The proprietary new use of the product or device according to claim 26, wherein at least one new essential adverse event comprises a drug interaction.
30. The proprietary new use of the product or device according to claim 26, wherein the at least one new essential adverse event is based upon neither a drug interaction, nor a chronic immune mediated disorder.

31. The system of claim 13, wherein commercialization comprises facilitating documentation of inventorship.
32. The system of claim 31, further comprising documenting date of inventorship.
33. A method for creating and using data associated with a product or device, wherein the method comprises the steps of:
 - accessing at least one adverse event data source that stores adverse event data associated with a product or device;
 - analyzing the adverse event data to identify new essential adverse events associated with the product or device;
 - creating at least one essential adverse event information database, wherein the creating step comprises analyzing data from the at least one adverse event data source to identify at least one new useful characteristic or use for the product or device responsive to identification of at least one new essential adverse event associated with the product or device, wherein the creating step further comprises storing essential adverse event information, and wherein the adverse event information includes the at least one new use or characteristic; and
 - commercializing essential adverse event information stored at the essential adverse event information database.
34. The method of claim 33, wherein accessing further comprises accessing the at least one adverse event data source comprising raw data from a plurality of different adverse events.
35. The method of claim 33, wherein accessing further comprises accessing data from the at least one adverse event data source comprising adverse event information regarding exposure to or use of the product or device.
36. The method of claim 35, wherein accessing further comprises accessing the at least one adverse event data source further comprising information regarding adverse events selected

from at least two categories selected from the group consisting of death, illness, hospitalization, missed work, medical costs, abnormal laboratory results and surgeries.

37. The method of claim 33, further accessing at least one data source comprising information relating to patents and patent applications.

38. The method of claim 33, further accessing at least one data source comprising information relating to raw commercial or sales data.

39. The method of claim 33, further comprising providing the at least one adverse event data source comprising adverse event data gathered from at least 5000 subjects.

40. The method of claim 39, further comprising providing the at least one adverse event data source comprising information regarding amount of use of the product or device or duration of exposure to the product or device by each subject.

41. The method of claim 39, further comprising providing the at least one adverse event data source comprising information regarding product post-exposure adverse event data, which is recorded in selected time increments, ranging from less than one hour to more than ten years.

42. The method of claim 33, wherein commercializing further comprises selling, leasing or licensing the newly identified product information.

43. The method of claim 33, wherein commercializing further comprises protecting the intellectual property interest in the newly identified product information.

44. The method of claim 33, wherein commercializing further comprises formatting the data relating to at least one new adverse event associated with exposure to, or use of the product or device, or documenting same, such that a manufacturer or distributor of the product or device must inform consumers, users or individuals responsible for the user, physicians or prescribers about at least one new adverse event associated with exposure to or use of the product or device.

45. The method of claim 33, further comprising determining the value of commercializing the at least one new characteristic or use determined from the at least one identified essential adverse event.

46. The method of claim 33, further identifying the at least one new use of the product or device as a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

47. The method of claim 33, wherein the product or device is commercially available, and further identifying the new use as comprising restricting exposure of the product or device to one of the high risk associated groups selected from the group consisting of high or low temperatures, chemicals, surfaces, pressures, electricity and sparks; or contact of the product or device with one of the group selected from the group consisting of skin, eyes, ears, respiratory surfaces, gastrointestinal surfaces and mucous membranes of the consumer; or exposure to a subpopulation group selected from the group consisting of children, pregnant women, consumers with specific allergies or medical conditions and animals; or exposure to a subpopulation defined by at least one consumer-identifying characteristic selected from the group consisting of sex, weight, age, race, genetic characteristics, medical condition, pregnancy status, presence of allergies, and use of medicines or medical devices.

48. The method of claim 33, wherein the essential adverse event data is proprietary.

49. A proprietary product or device created using the method of claim 33.

50. The product of claim 33, wherein the product is medical.

51. The product of claim 49, wherein the product is medical.

52. The product of claim 50, wherein the medical product is a generic drug.

53. The product of claim 51, wherein the medical product is a generic drug.
54. The product of claim 33, wherein the product is non-medical.
55. The product of claim 49, wherein the product is non-medical.
56. The device of claim 33, wherein the device is medical.
57. The device of claim 49, wherein the device is medical.
58. The device of claim 33, wherein the device is non-medical.
59. The device of claim 49, wherein the device is non-medical.
60. A proprietary kit containing a product or device, and labeling notifying a user of at least one new essential adverse event for the product or device, wherein the kit is created in accordance with claim 33.
61. A proprietary kit containing a product or device, and labeling notifying a user of at least one new essential adverse event for the product or device, wherein the kit is created in accordance with claim 46.
62. The method comprising using the proprietary kit of claim 60 in accordance with a proprietary new characteristic of, or use for, a product or device.
63. The method comprising using the proprietary kit of claim 61 in accordance with a proprietary new characteristic of, or use for, a product or device.
64. A proprietary new use for a commercially available product or device, wherein the new use is determined from the data provided by the method of claim 33.

65. The proprietary new use for a commercially available product or device according to claim 64, wherein the new use is protected as an intellectual property.

66. The proprietary new use for a commercially available product or device according to claim 64, wherein the new use comprises a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

67. The proprietary new use of the product or device according to claim 66, wherein at least one new adverse event comprises a drug interaction.

68. The proprietary new use of the product or device according to claim 66, wherein at least one new adverse event is based upon neither a drug interaction, nor a chronic immune mediated disorder

69. The method in accordance with claim 33, further comprising establishing a new safety data sheet for a commercially available product or device, wherein the safety data sheet identifies at least one new essential adverse event for the at least one product or device.

70. The method in accordance with claim 33, further comprising establishing a new safety data sheet, which lacks at least one proprietary non-essential adverse event for the at least one product or device.

71. The safety data sheet produced in accordance with claim 69.

72. The safety data sheet produced in accordance with claim 70.

73. The method in accordance with claim 33, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an

expected higher return for development costs associated with the product or device, or any combination thereof.

74. The method in accordance with claim 69, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an expected higher return for development costs associated with the product or device, or any combination thereof.

75. The method in accordance with claim 70, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an expected higher return for development costs associated with the product or device, or any combination thereof.

76. The method in accordance with claim 33, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

77. The method in accordance with claim 69, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

78. The method in accordance with claim 70, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

79. The method of claim 33, wherein commercialization comprises facilitating documentation of inventorship.

80. The method of claim 79, further comprising documenting date of inventorship.

81. The method of claim 79, wherein the product or device is commercially available and further comprising identifying the new use as a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

82. The method of claim 80, wherein the product or device is commercially available and further comprising identifying the new use as a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

83. The product or device of claim 49, wherein the product or device is commercially available and wherein the new use comprises a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

84. The method of using the proprietary kit of claim 60 comprising providing a proprietary new characteristic of, or use for the product of device, wherein the product or device is commercially available, and wherein the new use comprises a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

85. A method of establishing at least one new use for a product or device, wherein the method comprises the steps of:

comparing adverse event data associated with a product or device with previously known adverse events associated with the product or device;

observing in the adverse event data, at least one new adverse event associated with the product or device;

determining whether the new adverse event associated with the product or device is an essential adverse event; and

identifying at least one new useful characteristic of, or use for, the product or device responsive to the determination that the at least one new adverse event associated with the product or device is an essential adverse event.

86. The method of claim 85, further comprising identifying the at least one new use of the product or device as a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device and where the product or device is commercially available

87. The method of claim 85, wherein comparing the adverse event data further comprises comparing data from a plurality of different adverse events.

88. The method of claim 85, wherein comparing the adverse event data further comprises comparing adverse event information regarding exposure to or use of the product or device.

89. The method of claim 85, wherein comparing the adverse event data, further comprises comparing information regarding adverse events selected from the group consisting of death, illness, hospitalization, missed work, medical costs, abnormal laboratory results and surgeries.

90. The method of claim 85, further comprising assessing adverse event data comprising information relating to patents and patent applications.

91. The method of claim 85, further comprising accessing adverse event data comprising information relating to raw commercial or sales data.

92. The method of claim 85, further comprising providing adverse event data comprising adverse event data gathered from at least 5,000 subjects.

93. The method of claim 92, further comprising providing adverse event data comprising information regarding amount of use of the product or device or duration of exposure to the product or device by each subject.

94. The method of claim 92, further comprising providing adverse event data comprising information regarding product or device post-exposure adverse event data, which is recorded in selected time increments, ranging from less than one hour to more than ten years.

95. The method of claim 86, further comprising commercializing the at least one new use for the product or device after determining at least one new adverse event associated with exposure to or use of the product or device in consideration of potential commercial value of the new use.

96. The method of claim 95, wherein commercializing further comprises selling, leasing or licensing the newly identified product information.

97. The method of claim 95, wherein commercializing further comprises protecting the intellectual property interest in the newly identified product information.

98. The method of claim 95, wherein commercializing further comprises formatting the data relating to at least one new adverse event associated with exposure to or use of the product or device, or documenting same, such that a manufacturer or distributor of the product must inform consumers, users or individuals responsible for the user, physicians or prescribers about the at least one new adverse event associated with exposure to or use of the product or device.

99. The method of claim 85, further comprising screening the product or device for which at least one new characteristic or use has been determined from the at least one identified essential adverse event to determine the value of commercializing the at least one new characteristic or use.

100. The method of claim 85, further identifying the at least one new use of the product or device as a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

101. The method of claim 85, wherein the product or device is commercially available, and further identifying the new use as comprising restricting exposure of the product or device to one of the high risk associated group selected from the group consisting of high or low temperatures, chemicals, surfaces, pressures, electricity and sparks; or contact of the product with one of the group selected from the group consisting of skin, eyes, ears, respiratory surfaces, gastrointestinal surfaces and mucous membranes of the consumer, or exposure to a subpopulation group selected from the group consisting of children, pregnant women, consumers with specific allergies or medical conditions and animals; or exposure to a subpopulation defined by at least one consumer-identifying characteristic selected from the group consisting of sex, weight, age, race, genetic characteristics, medical condition, pregnancy status, presence of allergies, and use of medicines or medical devices.
102. The method of claim 85, wherein the essential adverse event data is proprietary.
103. The method of claim 86, wherein the essential adverse event data is proprietary.
104. The proprietary product or device created using the method of claim 85.
105. The proprietary product or device created using the method of claim 86.
106. The product of claim 85, wherein the product is medical.
107. The product of claim 86, wherein the product is medical.
108. The product of claim 104, wherein the product is medical.
109. The product of claim 105, wherein the product is medical.
110. The product of claim 106, wherein the medical product is a generic drug.

111. The product of claim 107, wherein the medical product is a generic drug.
112. The product of claim 108, wherein the medical product is a generic drug.
113. The product of claim 109, wherein the medical product is a generic drug.
114. The product of claim 85, wherein the product is non-medical.
115. The product of claim 86, wherein the product is non-medical.
116. The product of claim 104, wherein the product is non-medical.
117. The product of claim 105, wherein the product is non-medical.
118. The device of claim 85, wherein the device is medical.
119. The device of claim 86, wherein the device is medical.
120. The device of claim 104, wherein the device is medical.
121. The device of claim 105, wherein the device is medical.
122. The device of claim 85, wherein the device is non-medical.
123. The device of claim 86, wherein the device is non-medical.
124. The device of claim 104, wherein the device is non-medical.
125. The device of claim 105, wherein the device is non-medical.

126. A proprietary kit containing a product or device, and labeling notifying a user of at least one new essential adverse event for the product or device, wherein the kit being created in accordance with one of claims 85.

127. A proprietary kit containing a product or device, and labeling notifying a user of at least one new essential adverse event for the product or device, wherein the kit being created in accordance with one of claims 86.

128. A proprietary kit containing a product or device, and labeling notifying a user of at least one new essential adverse event for the product or device, wherein the kit being created in accordance with one of claims 104.

129. A proprietary kit containing a product or device, and labeling notifying a user of at least one new essential adverse event for the product or device, wherein the kit being created in accordance with one of claims 105.

130. The method comprising using the proprietary kit of claim 126 in accordance with a proprietary new useful characteristic of, or use for, a product or device.

131. The method comprising using the proprietary kit of claim 127 in accordance with a proprietary new useful characteristic of, or use for, a product or device.

132. The method comprising using the proprietary kit of claim 128 in accordance with a proprietary new useful characteristic of, or use for, a product or device.

133. The method comprising using the proprietary kit of claim 129 in accordance with a proprietary new useful characteristic of, or use for, a product or device.

134. A proprietary new use for a commercially available product or device, wherein the new use is determined from the data provided by the method of claim 85.

135. The proprietary new use for a commercially available product or device according to claim 134, wherein the new use is protected as intellectual property.

136. The proprietary new use for a commercially available product or device according to claim 134, wherein the use comprises a restricted use in one or more subgroups of consumers, and wherein the use is based on demographic data, and for which use additional testing of the consumers is not needed.

137. The proprietary new use of the product or device according to claim 136, wherein at least one new adverse event comprises a drug interaction.

138. The proprietary new use of the product or device according to claim 136, wherein at least one new adverse event is based upon neither a drug interaction, nor a chronic immune mediated disorder.

139. The method in accordance with claim 85, further comprising establishing a new safety data sheet, which identifies at least one new essential adverse event for the at least one product or device.

140. The method in accordance with claim 86, further comprising establishing a new safety data sheet, which identifies at least one new essential adverse event for the at least one product or device.

141. The method in accordance with claim 85, further comprising establishing a new safety data sheet, which lacks at least one proprietary non-essential adverse event for the at least one product or device.

142. The method in accordance with claim 86, further comprising establishing a new safety data sheet, which lacks at least one proprietary non-essential adverse event for the at least one product or device.

143. The safety data sheet produced in accordance with claim 139.

144. The safety data sheet produced in accordance with claim 140.

145. The safety data sheet produced in accordance with claim 141.

146. The safety data sheet produced in accordance with claim 142.

147. The method in accordance with claim 85, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an expected higher return for development costs associated with the product or device, or any combination thereof.

148. The method in accordance with claim 86, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an expected higher return for development costs associated with the product or device, or any combination thereof.

149. The method in accordance with claim 139, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an expected higher return for development costs associated with the product or device, or any combination thereof.

150. The method in accordance with claim 140, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an expected higher return for development costs associated with the product or device, or any combination thereof.

151. The method in accordance with claim 141, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an

expected higher return for development costs associated with the product or device, or any combination thereof.

152. The method in accordance with claim 142, further comprising using the method to produce lower costs for development of the product or device, or quicker time to market, or an expected higher return for development costs associated with the product or device, or any combination thereof.

153. The method in accordance with claim 85, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

154. The method in accordance with claim 86, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

155. The method in accordance with claim 139, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

156. The method in accordance with claim 140, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

157. The method in accordance with claim 141, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

158. The method in accordance with claim 142, further comprising using the method to develop at least one essential proprietary new method of screening a product or device for safety.

159. The method of claim 95, wherein commercialization comprises facilitating documentation of inventorship.
160. The method of claim 159, further comprising documenting date of inventorship.
161. A method of establishing a product safety data sheet which lacks at least one proprietary non-essential adverse event comprising:
 - comparing adverse event data of a commercially available product or device to proprietary adverse event information on the product or device;
 - determining at least one proprietary non-essential adverse event related characteristic or proprietary use to prevent the non-essential adverse event; and
 - creating a product data safety sheet lacking the proprietary adverse event information.
162. The method of claim 163, further comprising providing the proprietary adverse event information in a product safety data sheet prior to the comparison.
163. A product data safety sheet created by the method of claim 161.
164. A product data safety sheet created by the method of claim 162.
165. A computer for managing product- or device-related data comprising:
 - at least one database storing adverse event data associated with a product or device;
 - processor for accessing and analyzing data from the at least one database to assist in identifying new essential adverse events associated with the product or device, and to assist in identifying at least one new useful characteristic of, or use of, the product or device responsive to identification of at least one new essential adverse event associated with the product or device; and
 - essential adverse event information storage device for storing essential adverse event information, including the at least one new essential adverse event associated with

the product or device, and the at least one new characteristic of, or use for, the product or device identified by the processor.

166. The computer of claim 165, further comprising interfacing the processor with a user node, wherein at least one adverse event database resides on the computer.

167. The computer of claim 165, wherein the at least one database comprises raw data from a plurality of different adverse events.

168. The computer of claim 165, wherein the at least one database contains previously known or reported adverse event data associated with exposure to or use of the product or device.

169. The computer of claim 168, wherein the at least one database contains information regarding adverse events selected from the group consisting of death, illness, hospitalization, missed work, medical costs, abnormal laboratory results and surgeries.

170. The computer of claim 168, wherein the at least one database contains raw adverse event data associated with exposure to or use of the product or device.

171. The computer of claim 170, wherein the at least one database contains information relating to patents and patent applications.

172. The computer of claim 165, wherein the data accessed by the processor comprises adverse event data gathered from at least 5,000 subjects.

173. The computer of claim 171, wherein adverse event data accessed by the processor, further comprises information regarding amount of use of the product or device or duration of exposure to the product or device by each subject.

174. The computer of claim 171, wherein adverse event data accessed by the processor, further comprises information regarding product post-exposure adverse event data, which is recorded in selected time increments, ranging from less than one hour to more than ten years.

175. The computer of claim 165, wherein the processor further comprises a means for commercializing at least one new useful characteristic of or use of the product or device after determining at least one new adverse event associated with exposure to or use of the product or device in consideration of the potential commercial value of the new use.

176. The computer of claim 175, wherein the commercializing means comprises means for selling, leasing or licensing the newly identified product information.

177. The computer of claim 175, wherein the commercializing means comprises means for protecting the intellectual property interest in the newly identified product information.

178. The computer of claim 175, wherein the commercializing means comprises means for formatting the data relating to at least one new adverse event associated with exposure to or use of the product, or means for documenting same, such that a manufacturer or distributor of the product or device must inform consumers, users or individuals responsible for the user, physicians or prescribers about at least one new adverse event associated with exposure to or use of the product or device.

179. The computer claim 165, wherein the processor further comprises a means for determining the value of commercializing the at least one new useful characteristic or use determined from the at least one identified essential adverse event.

180. The computer of claim 165, wherein the at least one new use of the product or device comprises a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

181. The computer of claim 180, wherein the new use comprises restricting exposure of the product or device to one of the high risk associated group selected from the group consisting of high or low temperatures, chemicals, surfaces, pressures, electricity and sparks; or contact of the product or device with one of the group selected from the group consisting of skin, eyes, ears, respiratory surfaces, gastrointestinal surfaces and mucous membranes of the consumer, or exposure to a subpopulation group selected from the group consisting of children, pregnant women, consumers with specific allergies or medical conditions and animals; or exposure to a subpopulation defined by at least one consumer-identifying characteristic selected from the group consisting of sex, weight, age, race, genetic characteristics, medical condition, pregnancy status, presence of allergies, and use of medicines or medical devices; and wherein the computer subsequently evaluates whether the product or device is commercially available.

182. A proprietary product or device created using the computer of claim 165.

183. The product of claim 182, wherein the product is medical.

184. The product of claim 182, wherein the medical product is a generic drug.

185. The product of claim 182, wherein the product is non-medical.

186. The device of claim 182, wherein the device is medical.

187. The device of claim 182, wherein the device is non-medical.

188. A proprietary kit containing a product or device, and labeling notifying a user of at least one new essential adverse event for the product or device, wherein the kit is created in accordance with claim 165.

189. The method of using the proprietary kit of claim 188 in accordance with a proprietary new useful characteristic of, or use for, a product or device.

190. A proprietary new use for a commercially available product or device, wherein the new use is determined from the data provided by the computer of claim 165.

191. The proprietary new use for a commercially available product or device according to claim 190, wherein the new use is protected as an intellectual property.

192. The proprietary new use for a commercially available product or device according to claim 190, wherein the use comprises a restricted use in one or more subgroups of consumers, and wherein the use is based on demographic data, and for which use additional testing of the consumers is not needed.

193. The proprietary new use of a product or device according to claim 190, wherein the new adverse event comprises a drug interaction.

194. The proprietary new use of a product or device according to claim 190, wherein the new adverse event is based upon neither a drug interaction, nor a chronic immune mediated disorder.

195. The proprietary new use of a product or device according to claim 190, wherein the new use comprises a restricted use in at least one population subgroup when there is observed to be a high risk of at least one adverse event associated with exposure to or use of the product or device.

196. The computer of claim 175, wherein the means for commercializing comprises facilitating documentation of inventorship.

197. The computer of claim 196, wherein the means for commercializing further comprises documenting date of inventorship.

198. The computer of claim 165, wherein the at least one database comprises commercial or sales data.

199. A method of marketing or packaging a product or device, comprising including as part of the sale or transfer of the product or device, a contract, wherein the contract prohibits the use of the product or device by the buyer or buyer's representative for discovering or detecting one or more new essential adverse event or for developing a proprietary product or device, or proprietary screening method, based on the discovered or detected new essential adverse event.

200. The method of claim 199, wherein the contract further precludes the buyer or buyer's representative from patenting the discovered or detected new essential adverse event with regard to the product or device, or proprietary product or device resulting therefrom, or proprietary screening method related thereto.

2013-05-24 10:03:41